Kollagen Reagens HORM Suspension

1. Product

 

Collagen Reagens HORM® Suspension (KRH)

 

2. Manufacturer

 

Takeda production site in Linz, Austria, holder of  EN ISO 13485:2016+AC:2009 certifications for Medical Devices.

 

 

3. Categorisation of therapeutical area

 

Collagen Reagens HORM® can be categorized as a diagnostic product widely used in haematological laboratories and/or blood preservation institutions. It is a suspension of native collagen fibrils acting as inductor of platelet aggregation.

 

 

Blood coagulation is a highly complex and sophisticated system to maintain vascular integrity. In case of injuries, platelet adhesion to vessel wall collagen plays a fundamental role in initiating complex interactions that in the end lead to formation of platelet aggregates. These can be considered a “peg” that consequently tightens the injured vessel.

 

  • Disorders in the hemostasis system may lead to a series of severe conditions, such as myocardial infarction, strokes and peripheral arterial diseases.

 

  • Platelet and coagulation associated diseases comprise among others
    • Abnormal platelet counts (thrombocytopenia or thrombocytosis)
    • Different syndromes (Bernard Soulier syndrome, Glanzmann’s thrombasthenia, von Willebrand disease)
    • Drug induced malfunctions
    • Age induced malfunctions

 

4. Description of product

 

Collagen Reagens HORM® is a suspension of native equine tendon collagen (type I). It is classified an in-vitro diagnostic medical device used for the determination of platelet aggregation capacity. Collagen fibrils act as an inductor of platelet aggregation - the product  may therefore be used to

 

  • assess platelet function
  • detect von Willebrand disease/differentiate subtypes
  • predict possible risks with cardial interventions
  • monitor antithrombotic therapies (e.g. ASA [Aspirinâ])

 

5. Advantages and characteristics:

  • Can be used with different analytic equipments (types of aggregometers)
  • Different analytical methods (turbidimetric, electric impedance method)
  • Individual dilutions possible – no pre-fabricated cartridges
  • Equine origin
  • Native fibrillar structure
  • Suspension manufactured by a unique and very smooth process
  • Delivered directly

 

6. Packaging sizes

 

KRH is available as

  • set presentation composed of 1x4 ml reagent plus 4x10 ml diluting solution
  • diluting solution 5x10ml

 

7. Instructions for Use (03.2013)

 

8. Distribution/Contact/ /Questions

 

Mrs. Sandra Hutter

Takeda Austria GmbH

A-4020 Linz

St. Peter Strasse 25

Austria/Europe

Tel: +43 732 6919 4819

 

Email: collagenreagens@takeda.com

 

 

9. Frequently Asked Questions

 

Q: How is the adjustment of a pH-value between 2,7-2,9 done for the isotonic glucose solution (SKF solution)?

A: The adjustment is done with lactic acid.

 

Q: Do you have any antibody that reacts well with Collagen Reagens Horm?

A: No

 

Q: What are the dimensions of the standard box?

A: Collagen Reagens Horm, Takeda ref: 1130630  (1 vial collagen + 4 ampoules SKF solution) packed in polystyrol: 12 x 13,5 x 5 cm. Weight of the standard box: 109 grams

 

Q: What is the origin of Collagen Reagens Horm?

A: Country of origin is Austria.

 

Q: What type of collagen is Collagen Reagens Horm?

A: Collagen Reagens Horm is produced from equine tendons. The predominant collagen in tendons is Type I. We do not test our Collagen Reagens Horm batches specifically for their compositions of collagen types. As it is known from literature Collagen Reagens Horm contains a mixture of approximately 95% Collagen Type I and 5% Collagen Type III. (see literature reference Nr. 10: Favaloro E.J; Thromb. Haemost. 2000; 83: 127-135)

 

Q: What is the recommended shipping temperature?

A: Shipping temperature = storage temperature: + 2 to + 8 °C.

 

Q: Details of any temperature cycle assessments, i.e. permitted number of excursions from the specified shipping / storage temperature?

A: Maximum allowable cumulative time of temperature excursion +8 to + 25 °C = 1 day. No excursions below + 2°C allowed.

 

 

10.    Comprehensive Literature

 

1.     Born GV Cross MJ . The aggregation of blood platelets. J Physiol. 1963 Aug;168:178-95.

2.     Marx R, Schulte F. Über einen klinischen Schnelltest zur Erfassung von hereditären und erworbenen Thrombopathien. Blut.1972 Mar;24(3):137-41.

3.     Cardinal DC , Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135-58.

4.     Katthagen BD, Hellstern P. [In vitro studies on the effect of dissolved and undissolved heterologous collagen sponge on human thrombocytes] Z Orthop Ihre Grenzgeb. 1984 Sep-Oct;122(5):677-81.

5.     Riess H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol. 1986 Jan;85(1):50-6.

6.     Adelmann-Grill BC Otto K Immunological safety evaluation of a haemostatic agent and wound dressing made of horse collagen fibrils. Arzneimittelforschung. 1987 Jul;37(7):802-5.

7.     Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J. 1995 Mar 1;306 ( Pt 2):337-44 .

8.     Hathaway WE, Goodnight SH. Disorders of Hemostasis and Thrombosis: A Clinical Guide. 2nd ed., McGraw-Hill. 2000

9.     Siljander PR . Platelet-collagen interaction and microvesiculation, Academic dissertation, Faculty of Science of the University of Helsinki. 2000

10.   Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost . 2000 Jan;83(1):127-35.

11.   Favaloro EJ. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. Am J Clin Pathol. 2000 Oct;114(4):608-18.

12.   Jarvis GE, Atkinson BT, Snell DC, Watson SP. Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens. Br J Pharmacol. 2002 Sep;137(1):107-17.

13.   Paczuski R. Determination of von Willebrand factor activity with collagen-binding assay and diagnosis of von Willebrand disease: effect of collagen source and coating conditions. J Lab Clin Med . 2002 Oct;140(4):250-4.

14.   Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003 Jul 15;102(2):449-61.

15.   Breddin HK. Can platelet aggregometry be standardized? Platelets. 2005 May-Jun;16(3-4):151-8. Review.

16.   Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost. 2007 Nov;33(8):727-44. Review.

17. Smethurst PAOnley DJJarvis GEO'Connor MNKnight CGHerr ABOuwehand WHFarndale RW. Structural basis for the platelet-collagen interaction: the smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem. 2007 Jan 12;282(2):1296-304

Jänner 2018; AT/OTH/0517/0006